KLRA · CIK 0002096997
What Kailera Therapeutics, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for KLRA. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- China collaboration partner (Hengrui); BIOSECURE-style restrictions & trade tensionsmedium
Core licensor/manufacturer Hengrui is in China; legislation barring federal funding tied to certain Chinese companies could force Kailera to reevaluate the Hengrui relationship, and US-China trade tensions threaten supply and costs.
“government executive agency contract, grant, or loan funding to procure or obtain, or enter into, extend or renew contracts involving the use of certain equipment or services produced or provided by certain Chinese companies which could cause us to reevaluate our relationship with our certain of our existing manufacturing partners, including Hengrui.”
Sole-source dependency
- single-source reagents; offshore supply for drug substance/productmedium
Manufacturing depends on single-source reagents and specialized equipment that may be hard to secure; some supply originates outside the US, and termination/breach of supply or technology-transfer arrangements would materially harm the business.
“Manufacturing may also depend on raw materials, single source reagents or specialized equipment that may be difficult to secure. Because some supply originates outside the United States, any delay in obtaining or maintaining required import or export licenses or clearances could delay our timelines.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Jiangsu Hengrui Pharmaceuticals (Hengrui)
“We currently rely on third parties, including Hengrui, for supply of the active pharmaceutical ingredients, or API, drug substance or drug product, in our product candidates. Hengrui supplies us with drug substance and drug product for our clinical trials, but if the Hengrui License Agreement is terminated, then our supply from Hengrui will also be terminated.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch